Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations

ABP 980 (KANJINTI™, Amgen, Thousand Oaks, CA, USA; Amgen Europe B.V., The Netherlands) is a biosimilar to trastuzumab (Herceptin(®)), a monoclonal antibody that selectively binds human epidermal growth factor receptor-2 (HER2). Here we provide a brief overview of the totality of evidence (including...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolberg, Hans-Christian, Demetriou, Georgia Savva, Hanes, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Practical Approach
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297514/
https://www.ncbi.nlm.nih.gov/pubmed/33428085
http://dx.doi.org/10.1007/s40487-020-00129-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297514/
https://www.ncbi.nlm.nih.gov/pubmed/33428085
http://dx.doi.org/10.1007/s40487-020-00129-x

Ejemplares similares